Polygenic risk scores to refine Breast cancer screening and prevention strategies.

Breast cancer (BC) is the world's most prevalent cancer and can affect almost any post-pubertal woman. Early detection is associated with improved survival, and most high-income countries have adopted population-based screening programs to enhance early detection and survival although significant differences in screening age, methodology, and frequency exist. BC is known to be a heritable disease, with a small percentage of women having pathogenic variants in moderate or high-risk genes. However, Polygenic Risk Scores (PRS) incorporate many low penetrance single nucleotide polymorphisms (SNPs) and are the most powerful tool to help stratify women based on their personalized BC risk. PRS are particularly useful if incorporated into established risk prediction models (RPM). Risk stratification using PRS-containing RPMs can guide eligibility for enhanced screening and prevention programmes. This review discusses the role PRS plays in personalized risk prediction screening and prevention approaches as some of the challenges to their use.

• Publication year

  2025

• Venue

  Personalized Medicine

• Publication date

  2025-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17410541.2025.2581559PMID 41229331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention

  2025cited by this paper
• Risk stratification in breast screening workshop

  2024cited by this paper
• Development and evaluation of patient-centred polygenic risk score reports for glaucoma screening

  2024cited by this paper
• Women’s experiences of risk-stratified breast cancer screening in the MyPeBS trial: a qualitative comparative study across two European countries

  2024cited by this paper
• Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

  2024cited by this paper
• Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction

  2024cited by this paper
• Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes

  2024cited by this paper
• Feasibility and acceptability of offering breast cancer risk assessment to general population women aged 30–39 years: a mixed-methods study protocol

  2024cited by this paper
• Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

  2024cited by this paper
• Psychological impact of risk-stratified screening as part of the NHS Breast Screening Programme: multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420)

  2023cited by this paper
• The cost-effectiveness of risk-stratified breast cancer screening in the UK

  2023cited by this paper
• AI-based multi-PRS models outperform classical single-PRS models

  2023cited by this paper
• Estimating the Cost of 3 Risk Prediction Strategies for Potential Use in the United Kingdom National Breast Screening Program

  2023cited by this paper
• Article: Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent.

  2023cited by this paper
• Polygenic risk scores and breast cancer risk prediction

  2023cited by this paper
• MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40-70: focus on recruitment strategy in France

  2022cited by this paper
• Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition

  2022cited by this paper
• Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization

  2022cited by this paper
• Ethnic, gender and other sociodemographic biases in genome-wide association studies for the most burdensome non-communicable diseases: 2005–2022

  2022cited by this paper
• Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

  2022cited by this paper
• A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).

  2022cited by this paper
• Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel.

  2022cited by this paper
• Assessing agreement between different polygenic risk scores in the UK Biobank

  2022cited by this paper
• Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.

  2021cited by this paper
• The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?

  2021cited by this paper
• Potential of polygenic risk scores for improving population estimates of women’s breast cancer genetic risks

  2021cited by this paper
• Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score

  2021cited by this paper
• Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women

  2021cited by this paper
• Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

  2021cited by this paper
• Reaching the End-Game for GWAS: Machine Learning Approaches for the Prioritization of Complex Disease Loci

  2020cited by this paper
• Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease.

  2020cited by this paper
• Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes

  2020cited by this paper
• Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort

  2020cited by this paper
• Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

  2020cited by this paper
• 15 years of genome-wide association studies and no signs of slowing down

  2020cited by this paper
• Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB

  2020cited by this paper
• Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification

  2020cited by this paper
• Risk Models for Breast Cancer and Their Validation

  2019cited by this paper
• Performance of breast cancer risk assessment models in a large mammography cohort.

  2019cited by this paper
• Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35–39 at Increased Familial Risk of Breast Cancer

  2019cited by this paper
• Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

  2019cited by this paper
• BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors

  2019cited by this paper
• Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants

  2019cited by this paper
• Psychological impact of providing women with personalised 10-year breast cancer risk estimates

  2018cited by this paper
• The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches

  2018cited by this paper
• Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

  2018cited by this paper
• Common Genetic Variation and Breast Cancer Risk—Past, Present, and Future

  2018cited by this paper
• Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry

  2018cited by this paper
• Bayesian multiple logistic regression for case-control GWAS

  2018cited by this paper
• Breast cancer in young women: an overview

  2017cited by this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cited by this paper
• Human demographic history impacts genetic risk prediction across diverse populations

  2016cited by this paper
• Genomics is failing on diversity

  2016cited by this paper
• Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

  2016cited by this paper
• Developing and evaluating polygenic risk prediction models for stratified disease prevention

  2016cited by this paper
• The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance

  2016cited by this paper
• Breast cancer risk feedback to women in the UK NHS breast screening population

  2016cited by this paper
• Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

  2013cited by this paper
• Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

  2013cited by this paper
• Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study

  2013cited by this paper
• Large-scale genotyping identifies 41 new loci associated with breast cancer risk

  2013cited by this paper
• Aromatase, aromatase inhibitors, and breast cancer.

  2011cited by this paper
• Exemestane for breast-cancer prevention in postmenopausal women.

  2011cited by this paper
• Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

  2011cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.

  2010cited by this paper
• Receiver operating characteristic curve in diagnostic test assessment.

  2010cited by this paper
• SERMs for the treatment and prevention of breast cancer

  2007cited by this paper
• SNPs in disease gene mapping, medicinal drug development and evolution

  2007cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004cited by this paper
• Oestrogen exposure and breast cancer risk

  2003cited by this paper
• Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

  1999cited by this paper
• Genome-wide association study identi fi es common variants associated with breast cancer in South African Black women

  year unknowncited by this paper

• No citing papers are available for this paper.